Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder.
Krystian KaczmarekHenning PlageKira FurlanoSebastian HofbauerSarah WeinbergerBernhard RallaAntonia FranzAnnika FendlerMichela de MartinoFlorian RoßnerSimon SchallenbergSefer ElezkurtajMartina KluthMaximilian LennartzNiclas C BlessinAndreas H MarxHenrik SamtlebenMargit FischMichael RinkMarcin SlojewskiThorsten EckeSteffen HallmannStefan KochNico AdaminiSarah MinnerRonald SimonGuido SauterJoachim WeischenfeldtTobias KlatteThorsten SchlommDavid HorstHenrik ZechaPublished in: International urology and nephrology (2023)
In summary, the results of our study demonstrate that Upk1a and/or Upk1b immunohistochemistry can complement GATA3 for the distinction of urothelial carcinomas. Furthermore, a progressive loss of Upk1a/b expression during stage progression and a prognostic role of the combination GATA3/Upk1a/Upk1b in pT4 carcinomas is evident.